Direct answer
How to compare potency, efficacy and signalling bias across GLP-1, GIP and glucagon receptor assays without overinterpreting platform effects.
- Potency is the concentration associated with a defined response in a defined system; it is not a universal rank.
- Efficacy describes the attainable response relative to a reference and can be masked by receptor reserve.
- Claims of signalling bias require matched assays and an explicit quantitative framework.
What is the difference between potency and efficacy?
Potency is commonly summarized by an EC50, the concentration associated with half of the fitted response range. Efficacy concerns the response a ligand can produce in that system. A ligand can appear potent but have a lower maximal response, or appear less potent while reaching the same maximum.
Both values depend on receptor density, coupling and assay amplification. They should be reported with the reference agonist and experimental system, not used as free-standing properties.
What is receptor reserve?
When a cell expresses more receptor than is needed for a full downstream response, partial occupancy can produce a maximal signal. This reserve shifts apparent potency and can hide partial agonism. Reporter lines optimized for large assay windows may therefore exaggerate similarity between ligands.
Reduce uncertainty by comparing more than one expression level or using a proximal readout. An irreversible antagonist or controlled receptor titration can help characterize reserve, depending on the system.
When is signalling bias a valid conclusion?
Bias describes a ligand preference among signalling pathways relative to a reference ligand. Different EC50 values in cAMP and arrestin assays are not enough if those assays have different receptor expression or amplification. Normalize to a common reference and use an analytical model that accounts for system effects.
Replicate the finding in a physiologically relevant cell where possible. Describe bias as conditional on the tested system. Do not turn a platform-specific estimate into a universal mechanism.
How can three receptors be compared?
For multi-agonists, use matched host cells, receptor constructs, assay chemistry and plate conditions. Run reference agonists for each receptor and express the test ligand relative to those standards. If one receptor assay has a very different signal window or reserve, state that a simple potency ratio is uncertain.
Consider albumin and adsorption because acylated peptides can show platform-dependent recovery. Measure material content and use the same preparation across the three assays.
What should a publication show?
Publish full curves, replicate points, confidence intervals, maximal responses, fitting constraints and independent experiment counts. Provide receptor species and expression information. A transparent dataset lets other laboratories decide whether an apparent receptor balance reflects the ligand or the assay.
Continue through the evidence
Methods and quality. GLP-1 Receptor Assay Design: Controls, Curves and Interpretation, Glucagon Receptor Experiments in Triple-Agonist Research, Peptide Dose-Response Curves: EC50, Emax and Assay Design, How to Read a Peptide Certificate of Analysis, HPLC Peptide Purity: How to Read a Chromatogram Without Overclaiming, LC-MS for Peptide Identity: Molecular Mass, Charge States and Sequence Evidence and Albumin Binding and Acylated Peptides: A Research Methods Guide.
Connected peptide briefings. GIP Receptor Pharmacology: Why the Experimental Context Matters, Research Peptides in Canada: A Laboratory Procurement Guide, Health Canada, Peptides and Research Use Only: What the 2026 Guidance Means, Shipping and Storing Research Peptides Across Canada and Incretin Research: GLP-1, GIP and the Move to Multi-Receptor Agonists.
Sources and further literature
- Structural insights into retatrutide triple agonismCryo-EM and receptor-structure study, 2024.
- A rationally designed monomeric peptide triagonist in rodent modelsFoundational preclinical triagonist paper, Nature Medicine, 2015.
- Retatrutide structural comparison with GLP-1R, GIPR and GCGR agonistsIncludes structural and functional receptor comparisons.
North Specs separates scientific education from product claims. Review primary literature, current regulations and institutional requirements before designing laboratory work.
